title: The new face of ovarian cancer modeling: better prospects for detection and treatment.
abstract: Ovarian cancer has a disproportionately high mortality rate because patients typically present with late-stage metastatic disease. The vast majority of these deaths are from high-grade serous carcinoma. Recent studies indicate that many of these tumors arise from the fallopian tube and subsequently metastasize to the ovary. This may explain why such tumors have not been detected at early stage as detection efforts have been focused purely on the ovary. In keeping with this leap in understanding other advances such as the development of ex-vivo models and immortalization of human fallopian tube epithelial cells, and the use of integrated genomic analyses to identify hundreds of novel candidate oncogenes and tumor suppressors potentially involved in tumorigenesis now engender hope that we can begin to truly define the differences in pathogenesis between fallopian tube and ovarian-derived tumors. In doing so, we can hopefully improve early detection, treatment, and outcome.
authors.affiliation: Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute 450 Brookline Avenue, Boston, MA 02215 USA.
authors.forename: Alison M
authors.initials: AM
authors.lastname: Karst
authors.forename: Ronny
authors.initials: R
authors.lastname: Drapkin
references.citation: Nature. 2011 Jun 29;474(7353):609-15
references.pmid: 21720365
references.citation: Lancet Oncol. 2008 Dec;9(12):1191-7
references.pmid: 19038766
references.citation: J Vis Exp. 2011 May 09;(51):
references.pmid: 21610668
references.citation: Exp Cell Res. 1995 Jun;218(2):499-507
references.pmid: 7796885
references.citation: Nat Rev Cancer. 2004 Oct;4(10):814-9
references.pmid: 15510162
references.citation: BJOG. 2011 Mar;118(4):429-32
references.pmid: 21244617
references.citation: Am J Obstet Gynecol. 2010 Dec;203(6):584.e1-22
references.pmid: 20965493
references.citation: Nature. 2003 Mar 20;422(6929):322-6
references.pmid: 12646923
references.citation: Int J Cancer. 2011 May 1;128(9):2063-74
references.pmid: 20635389
references.citation: Am J Obstet Gynecol. 2011 Jan;204(1):19.e1-6
references.pmid: 20619389
references.citation: Gynecol Oncol. 2011 Mar;120(3):470-3
references.pmid: 21159368
references.citation: Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12372-7
references.pmid: 21746896
references.citation: J Oncol. 2010;2010:932371
references.pmid: 19746182
references.citation: Mol Oncol. 2009 Apr;3(2):171-81
references.pmid: 19383379
references.citation: Am J Obstet Gynecol. 1992 Sep;167(3):729-35
references.pmid: 1326894
references.citation: J Pathol. 2010 May;221(1):49-56
references.pmid: 20229506
references.citation: Proc Natl Acad Sci U S A. 2011 May 3;108(18):7547-52
references.pmid: 21502498
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5284-93
references.pmid: 18854563
references.citation: Cancer Res. 2009 May 1;69(9):4036-42
references.pmid: 19383911
references.citation: Am J Surg Pathol. 2010 Mar;34(3):433-43
references.pmid: 20154587
references.citation: Nat Genet. 2010 Oct;42(10):874-9
references.pmid: 20852632
references.citation: Clin Cancer Res. 2009 Feb 15;15(4):1417-27
references.pmid: 19193619
references.citation: BMC Cancer. 2008 Jan 22;8:17
references.pmid: 18208621
references.citation: Br J Cancer. 2009 Jan 27;100(2):412-20
references.pmid: 19127255
references.citation: Nat Genet. 2010 Oct;42(10):880-4
references.pmid: 20852633
references.citation: Int J Gynecol Pathol. 2011 Jan;30(1):4-11
references.pmid: 21131840
references.citation: Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9
references.pmid: 17218844
references.citation: Adv Anat Pathol. 2009 Sep;16(5):267-82
references.pmid: 19700937
references.citation: Oncogene. 2010 Feb 25;29(8):1103-13
references.pmid: 19935705